Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

J&J And Amgen Cut Staff In U.S.

by Rick Mullin
April 20, 2009 | A version of this story appeared in Volume 87, Issue 16

Johnson & Johnson will eliminate about 900 positions in its Ortho-McNeil-Janssen Pharmaceuticals division. The cutbacks, which will mainly affect U.S. salespeople, represent about 6% of the division's staff. Meanwhile, Amgen will consolidate its clinical manufacturing operations in Thousand Oaks, Calif., eliminating 100 positions at a facility in Bothell, Wash. The Bothell facility, which came with Amgen's 2002 acquisition of Immunex, will continue to house oncology research in conjunction with a center in Seattle.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.